guest ::
| Home > Publications database > Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: Response, Progression, and Pseudoprogression > print |
| Home > Publications database > Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: Response, Progression, and Pseudoprogression > print |
| 001 | 864681 | ||
| 005 | 20220930130217.0 | ||
| 024 | 7 | _ | |a 10.1093/neuonc/noz147 |2 doi |
| 024 | 7 | _ | |a 1522-8517 |2 ISSN |
| 024 | 7 | _ | |a 1523-5866 |2 ISSN |
| 024 | 7 | _ | |a 2128/23923 |2 Handle |
| 024 | 7 | _ | |a altmetric:65374265 |2 altmetric |
| 024 | 7 | _ | |a pmid:31437274 |2 pmid |
| 024 | 7 | _ | |a WOS:000522635600005 |2 WOS |
| 037 | _ | _ | |a FZJ-2019-04375 |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Galldiks, Norbert |0 P:(DE-Juel1)143792 |b 0 |e Corresponding author |
| 245 | _ | _ | |a Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: Response, Progression, and Pseudoprogression |
| 260 | _ | _ | |a Oxford |c 2020 |b Oxford Univ. Press |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1579511994_29416 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a The advent of immunotherapy using immune checkpoint inhibitors (ICIs) and targeted therapy (TT) has dramatically improved the prognosis of various cancer types. However, following ICI therapy or TT—either alone (especially ICI) or in combination with radiotherapy—imaging findings on anatomical contrast-enhanced MRI can be unpredictable and highly variable, and are often difficult to interpret regarding treatment response and outcome. This review aims at summarizing the imaging challenges related to TT and ICI monotherapy as well as combined with radiotherapy in patients with brain metastases, and to give an overview on advanced imaging techniques which potentially overcome some of these imaging challenges. Currently, major evidence suggests that imaging parameters especially derived from amino acid PET, perfusion-/diffusion-weighted MRI, or MR spectroscopy may provide valuable additional information for the differentiation of treatment-induced changes from brain metastases recurrence and the evaluation of treatment response. |
| 536 | _ | _ | |a 572 - (Dys-)function and Plasticity (POF3-572) |0 G:(DE-HGF)POF3-572 |c POF3-572 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef |
| 700 | 1 | _ | |a Kocher, Martin |0 P:(DE-Juel1)173675 |b 1 |
| 700 | 1 | _ | |a Ceccon, Garry |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a Werner, Jan-Michael |0 P:(DE-HGF)0 |b 3 |
| 700 | 1 | _ | |a Brunn, Anna |0 P:(DE-HGF)0 |b 4 |
| 700 | 1 | _ | |a Deckert, Martina |0 P:(DE-HGF)0 |b 5 |
| 700 | 1 | _ | |a Pope, Whitney B |0 P:(DE-HGF)0 |b 6 |
| 700 | 1 | _ | |a Soffietti, Riccardo |0 P:(DE-HGF)0 |b 7 |
| 700 | 1 | _ | |a Le Rhun, Emilie |0 P:(DE-HGF)0 |b 8 |
| 700 | 1 | _ | |a Weller, Michael |0 P:(DE-HGF)0 |b 9 |
| 700 | 1 | _ | |a Tonn, Jörg C |0 P:(DE-HGF)0 |b 10 |
| 700 | 1 | _ | |a Fink, Gereon R |0 P:(DE-Juel1)131720 |b 11 |
| 700 | 1 | _ | |a Langen, Karl-Josef |0 P:(DE-Juel1)131777 |b 12 |
| 773 | _ | _ | |a 10.1093/neuonc/noz147 |g p. noz147 |0 PERI:(DE-600)2094060-9 |n 1 |p 17-30 |t Neuro-Oncology |v 22 |y 2020 |x 1523-5866 |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/864681/files/20191113124209165.pdf |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/864681/files/noz147.pdf |y Restricted |
| 856 | 4 | _ | |x pdfa |u https://juser.fz-juelich.de/record/864681/files/20191113124209165.pdf?subformat=pdfa |
| 856 | 4 | _ | |y Published on 2019-08-22. Available in OpenAccess from 2020-08-22. |u https://juser.fz-juelich.de/record/864681/files/Galldiks_2019_Post%20Print_Neuro%20Oncol_Imaging%20challenges%20of%20immunotherapy.pdf |
| 856 | 4 | _ | |y Published on 2019-08-22. Available in OpenAccess from 2020-08-22. |x pdfa |u https://juser.fz-juelich.de/record/864681/files/Galldiks_2019_Post%20Print_Neuro%20Oncol_Imaging%20challenges%20of%20immunotherapy.pdf?subformat=pdfa |
| 856 | 4 | _ | |x pdfa |u https://juser.fz-juelich.de/record/864681/files/noz147.pdf?subformat=pdfa |y Restricted |
| 909 | C | O | |o oai:juser.fz-juelich.de:864681 |p openaire |p open_access |p OpenAPC |p driver |p VDB |p openCost |p dnbdelivery |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 0 |6 P:(DE-Juel1)143792 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 1 |6 P:(DE-Juel1)173675 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 11 |6 P:(DE-Juel1)131720 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 12 |6 P:(DE-Juel1)131777 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l Decoding the Human Brain |1 G:(DE-HGF)POF3-570 |0 G:(DE-HGF)POF3-572 |2 G:(DE-HGF)POF3-500 |v (Dys-)function and Plasticity |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |
| 914 | 1 | _ | |y 2020 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a Embargoed OpenAccess |0 StatID:(DE-HGF)0530 |2 StatID |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b NEURO-ONCOLOGY : 2017 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b NEURO-ONCOLOGY : 2017 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |
| 920 | _ | _ | |l yes |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-3-20090406 |k INM-3 |l Kognitive Neurowissenschaften |x 0 |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-4-20090406 |k INM-4 |l Physik der Medizinischen Bildgebung |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-Juel1)INM-3-20090406 |
| 980 | _ | _ | |a I:(DE-Juel1)INM-4-20090406 |
| 980 | _ | _ | |a APC |
| 980 | 1 | _ | |a APC |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|